Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$26.1B

May6Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc is a healthcare company that focuses on acquiring and managing revenue-generating pharmaceutical royalties. With a market cap of $25 billion, it plays a significant role in the pharmaceutical industry by providing funding to biopharmaceutical companies, which can help bring new drugs to market more efficiently.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$1.18

Revenue

Revenue figures provide insight into the company's sales performance and growth potential, reflecting demand for its royalty agreements.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma did not provide specific guidance, but historical performance suggests a focus on maintaining or growing its royalty revenue. The company continues to navigate a competitive pharmaceutical landscape.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report solid earnings this quarter, with consensus estimates suggesting stable revenue and earnings growth. Investors are keen to see if the company can meet or exceed these expectations.

Bull Case

If Royalty Pharma exceeds EPS and revenue estimates, it could signal strong demand for its royalty agreements and potentially lead to a positive revaluation of the stock.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects, leading to a negative reaction from investors.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$874M

Revenue figures provide insight into the company's sales performance and growth potential, reflecting demand for its royalty agreements.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet or exceed the consensus estimate of $1.18?

This figure is crucial as it directly reflects the company's profitability and can significantly influence investor sentiment.

What are the revenue figures compared to the consensus of $874M?

Revenue performance is a key indicator of the company's growth trajectory and ability to generate cash flow.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Royalty Pharma to exceed its revenue targets due to recent successful drug launches that could boost royalty income.

Supporting Evidence

The options market is pricing a 4.5% move, suggesting uncertainty that could be mispriced given the company's historical performance.

There has been no recent insider activity, indicating that management may not be overly concerned about the upcoming results.

Key Risk

If the revenue exceeds $900M, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Royalty Pharma can sustain its earnings growth in a competitive market.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong profitability and investor confidence.

Bear Confirmed If

An EPS below $1.15 would raise concerns about the company's financial health and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

The options market is pricing in a potential movement of about 4.5% in either direction following the earnings report, indicating some uncertainty among investors.

Detail

30d HV

21.5%

Calls (400)P/C Ratio: 0.75Puts (300)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 2.89% on the day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around 2.09% based on historical patterns, as it would raise doubts about the company's growth potential.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships that could impact revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into the performance of key drugs generating royalties.
4Any guidance on future earnings or revenue expectations.
5Discussion on cost management and operational efficiency.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$1.18

Revenue

Revenue figures provide insight into the company's sales performance and growth potential, reflecting demand for its royalty agreements.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Royalty Pharma exceeds EPS and revenue estimates, it could signal strong demand for its royalty agreements and potentially lead to a positive revaluation of the stock.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects, leading to a negative reaction from investors.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.18

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$874M

Revenue figures provide insight into the company's sales performance and growth potential, reflecting demand for its royalty agreements.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet or exceed the consensus estimate of $1.18?

This figure is crucial as it directly reflects the company's profitability and can significantly influence investor sentiment.

What are the revenue figures compared to the consensus of $874M?

Revenue performance is a key indicator of the company's growth trajectory and ability to generate cash flow.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Royalty Pharma to exceed its revenue targets due to recent successful drug launches that could boost royalty income.

Supporting Evidence

The options market is pricing a 4.5% move, suggesting uncertainty that could be mispriced given the company's historical performance.

There has been no recent insider activity, indicating that management may not be overly concerned about the upcoming results.

Key Risk

If the revenue exceeds $900M, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Royalty Pharma can sustain its earnings growth in a competitive market.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong profitability and investor confidence.

Bear Confirmed If

An EPS below $1.15 would raise concerns about the company's financial health and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

The options market is pricing in a potential movement of about 4.5% in either direction following the earnings report, indicating some uncertainty among investors.

Detail

30d HV

21.5%

Calls (400)P/C Ratio: 0.75Puts (300)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests the stock could rise by an average of 2.89% on the day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around 2.09% based on historical patterns, as it would raise doubts about the company's growth potential.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships that could impact revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into the performance of key drugs generating royalties.
4Any guidance on future earnings or revenue expectations.
5Discussion on cost management and operational efficiency.